2. Academic Validation
  3. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents

Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents

  • Eur J Med Chem. 2008 Dec;43(12):2800-6. doi: 10.1016/j.ejmech.2007.12.015.
Ravindra K Rawal 1,  Rajkamal Tripathi,  S B Katti,  Christophe Pannecouque,  Erik De Clercq
Affiliations

Affiliation

  • 1 Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow 226 001, India.
PMID: 18242784 DOI: 10.1016/j.ejmech.2007.12.015
Abstract

A series of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones were designed, synthesized and evaluated as selective human immunodeficiency virus type-1 Reverse Transcriptase (HIV-1 RT) Enzyme inhibitors. The results of the HIV-1 RT kit and in vitro cell based assay showed that eight compounds effectively inhibited HIV-1 replication at 20-320 nM concentrations with minimal cytotoxicity in MT-4 as well as in CEM cells.

Figures